R1V Stock Chart & Stats
€4.82
€0.10(2.12%)
At close: 4:00 PM EDT
€4.82
€0.10(2.12%)
Day’s Range― - ―
52-Week Range€3.92 - €5.50
Previous CloseN/A
Volume0.00
Average Volume (3M)102.00
Market Cap
€238.90M
Enterprise Value€196.48
Total Cash (Recent Filing)€13.29M
Total Debt (Recent Filing)€5.82M
Price to Earnings (P/E)25.8
Beta0.22
Next Earnings
Oct 19, 2026EPS Estimate
0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.16
Shares Outstanding47,997,290
10 Day Avg. Volume197
30 Day Avg. Volume102
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)5.93
Price to Sales (P/S)4.21
P/FCF Ratio20.67
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)<0.01
Revenue Forecast (FY)€656.37K
Bulls Say, Bears Say
Bulls Say
High And Sustainable MarginsTristel’s persistently high gross margin and elevated adjusted EBITDA reflect proprietary disinfectant chemistry and a consumables-heavy model that drives durable unit economics. These margins support reinvestment in commercial expansion, fund dividends, and provide resilience to modest pricing or input cost swings.
Strong Balance Sheet And LiquidityLow leverage and a solid equity base give Tristel financial flexibility to fund targeted commercial hires, clinical studies, and insourcing capex without relying on external financing. A robust cash position reduces refinancing risk and supports a progressive dividend policy over the medium term.
Recurring Consumables Model With Growing U.S. TractionThe consumables-led business yields repeatable revenue tied to procedure volumes, creating strong lifetime value. Accelerating U.S. adoption, expanding distributor/OEM partnerships and product launches increase addressable market and scale potential, supporting multi-year revenue growth targets.
Bears Say
China And APAC Demand WeaknessExposure to APAC and China creates structural revenue volatility when local healthcare financing, private hospital stability, or regulatory trends change. Prolonged weakness could slow group growth, force re-prioritisation of resources, and constrain margin recovery in affected markets over several quarters.
Declining Free Cash Flow GrowthA drop in FCF growth signals potential pressures from working capital, capex or transitional operating spend tied to insourcing and hires. If the decline persists it could constrain M&A optionality, limit faster commercial investment or temper dividend progression despite healthy operating cash conversion.
Margin Pressure From Insourcing And Higher Operating SpendShifting wipes production in-house and increased recruitment/clinical investment raise depreciation and operating costs near term. One-off write-offs and elevated spend can compress margins and delay payback from scale; sustained higher cost base risks eroding expected EBITDA expansion if efficiencies lag.
Tristel News
R1V FAQ
What was Tristel PLC’s price range in the past 12 months?
Tristel PLC lowest stock price was €3.92 and its highest was €5.50 in the past 12 months.
What is Tristel PLC’s market cap?
Tristel PLC’s market cap is €238.90M.
When is Tristel PLC’s upcoming earnings report date?
Tristel PLC’s upcoming earnings report date is Oct 19, 2026 which is in 74 days.
How were Tristel PLC’s earnings last quarter?
Tristel PLC released its earnings results on Mar 02, 2026. The company reported €0.11 earnings per share for the quarter, beating the consensus estimate of €0.107 by €0.002.
Is Tristel PLC overvalued?
According to Wall Street analysts Tristel PLC’s price is currently Overvalued.
Does Tristel PLC pay dividends?
Tristel PLC does not currently pay dividends.
What is Tristel PLC’s EPS estimate?
Tristel PLC’s EPS estimate is 0.1.
How many shares outstanding does Tristel PLC have?
Tristel PLC has 47,997,290 shares outstanding.
What happened to Tristel PLC’s price movement after its last earnings report?
Tristel PLC reported an EPS of €0.11 in its last earnings report, beating expectations of €0.107. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Tristel PLC?
Currently, no hedge funds are holding shares in DE:R1V
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tristel Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
8.81%
12-Months-Change
Fundamentals
Return on Equity
3.36%
Trailing 12-Months
Asset Growth
6.03%
Trailing 12-Months
Company Description
Tristel PLC
Tristel plc is a company specializing in the creation, production, and global distribution of products designed to prevent infections, serving both its home market in the UK and international clients. Its operations are structured around three core divisions: the decontamination of medical devices within hospital environments, the disinfection of hospital-based environmental surfaces, and an additional 'Other' category. The firm offers an extensive range of disinfection solutions for medical instruments under its Tristel brand. These solutions are applied across a wide spectrum of clinical areas, including airway management, cardiology, ear, nose and throat (ENT), endoscopy, gastrointestinal physiology, laboratory applications, ophthalmology, phlebotomy, reproductive health/IVF, general surface disinfection, ultrasound, urology, and women's health, alongside other specialized products. Tristel plc was established in 1993 and has its main office situated in Snailwell, United Kingdom.
Technical Analysis
Advanced Medical Solutions
―
ConvaTec
―
CVS Group plc
―
Surgical Innovations
―
Smith & Nephew
―